Clinical

A recent study attempted to determine the prevalence of eosinophilic esophagitis (EoE) in a group of patients allergic to milk or egg and undergoing oral immunotherapy (OIT) to those foods, as well as describe its management and treatment pathway.

The findings, which contradict prior North American studies, suggest that the incidence rate of the rare cancer continues to increase in the United States.

Quantifying the risk of malignant melanoma from methotrexate use proved difficult in this new study, with the authors calling for larger studies with longer follow-up to guide future practice in the space.

The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC).

This analysis of 5 studies found that, compared with placebo, all biologic regimens improved Psoriasis Area and Severity Index (PASI) 90 response—considered a gold standard goal due to its correlation with quality of life.

A significant portion of patients who receive chimeric antigen receptor (CAR) T-cell therapy experience immune effector cell–associated neurotoxicity syndrome, and this recent study suggests neurofilament light chain protein levels may hold promise as a biomarker to identify at-risk patients.

Paul Sapia, MHA, acknowledges the underdiagnosis in CKD and explains how payers can incentivize screening going forward.

Dr Rajiv Agarwal explains the screening process for patients with CKD, including those who are asymptomatic.

An estimated 1 in 4 patients treated with durvalumab and chemotherapy (gemcitabine plus cisplatin) was alive at 2 years compared with 1 in 10 treated with chemotherapy alone, with these results contributing to the FDA's approval of the first immunotherapy to treat these cancers.

The case emphasizes the importance for clinician awareness of the potential for rare immune-mediated disorders, including acquired hemophilia A (AHA), following allogeneic hematopoietic stem cell transplantation (HSCT).

A new therapeutic paradigm has heightened the need for meaningful measures of assessing patients.

The management of myeloproliferative neoplasms (MPNs) in adolescent and young adult (AYA) patients is currently similar to that of older patients. However, comprehensive research is needed to form guidelines for this younger population.

Experts discuss improving outcomes for patients with heart failure through appropriate and timely switches to ARN inhibitors.

The panel explores clinical evaluations, such as the PROVE-HF study and PARADIGM-HF trial.

Frank J. Palella Jr, MD, and Carl Schmid continue the discussion of patient selection for long-acting injectable PrEP and its cost effectiveness in comparison with other PrEP modalities.

Dr Lynne H. Milgram starts the conversation on choosing the right candidate for long-acting injectable PrEP, as well as how findings show it is cost effective.

Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo.

Comorbidities and disease states associated with vitiligo are explored by a panel of key opinion leaders.

Post hoc analyses of the phase 3 PEGASUS trial found that clinical and hematological improvements were associated with better patient-reported fatigue and physical function outcomes in paroxysmal nocturnal hemoglobinuria, for an overall bettering of health-related quality of life (HRQOL).

Jeffrey Feldman, MD, details the clinical burden of CKD management, and Bertram Pitt, MD, discusses the impact CKD can have on patients at risk for cardiovascular disease.

Paul Sapia, MHA, explains the economic burden of treating chronic kidney disease.

The findings mean it may be feasible to use adult systemic lupus nephritis (SLE) trial data to reduce the data needed for pediatric indications.

With evidence lacking on the role of inflammation in nasal polyposis (NP), this study investigated the role of 2 potential biomarkers in the nasal secretions of patients who have NP concomitant with aspirin-exacerbated respiratory disease.

This new study investigated risk factors for cardiovascular disease, including heart failure, among hospitalized patients with a recent history of methamphetamine use and priority patient populations to target.

Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.

The real-world study adds to previous randomized controlled trial findings suggesting that shorter courses of antibiotic therapy can be sufficient for hospitalized patients with mild or moderate community-acquired pneumonia.

New research suggests Nestin expression can help distinguish combined hepatocellular-cholangiocarcinomas (CCAs) from hepatocellular carcinomas and intrahepatic cholangiocarcinomas.

Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.

In the phase 3 trial, Pfizer’s vaccine was 85.7% effective against respiratory syncytial virus (RSV) defined by 3 or more symptoms among older adults.

David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo.